Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergisticall...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Karp, Judith E., Flatten, Karen, Feldman, Eric J., Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E., Ritchie, Ellen, Smith, B. Douglas, Ironside, Valerie, Talbott, Timothy, Roboz, Gail, Le, Son B., Meng, Xue Wei, Schneider, Paula A., Dai, Nga T., Adjei, Alex A., Gore, Steven D., Levis, Mark J., Wright, John J., Garrett-Mayer, Elizabeth, Kaufmann, Scott H.
Format: Artigo
Język:Inglês
Wydane: American Society of Hematology 2009
Hasła przedmiotowe:
Clinical Trials and Observations
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686135/
https://ncbi.nlm.nih.gov/pubmed/19109557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-08-172726
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy